维拉帕米二甲双胍联合用药对高血压合并Ⅱ型糖尿病患者降压及降糖作用临床观察

目的观察维拉帕米二甲双胍联合用药对高血压合并2型糖尿病（diabetes mellitus,DM）患者降压及降糖作用。方法将129例高血压合并2型DM患者分为2组,维拉帕米治疗组98例,对照组31例。（1）维拉帕米治疗组：盐酸维拉帕米缓释胶囊180mg／d,二甲双胍750—1500mg／a,缬沙坦80～160mg／d,阿司匹林100mg／d;（2）对照组,缬沙坦80～160mg／d,盐酸维拉帕米缓释胶囊180mg／d,阿司匹林100ms／a;（3）血压观测：受试患者早7：00及晚22：00,每日测量2次,记录收缩压（SBP）及舒张压（DBP）。结果①二甲双胍2周后收缩压及舒张压与治疗前比较明显下降,4,6周后血压降到正常范围,治疗后比较差异具有显著性（P〈0．01）;②对照组治疗6周后自身比较差异有显著性（P〈0．01）,但血压未降到正常范围;③两组治疗6周后比较差异具有显著性（P〈0．01）,维拉帕米治疗组明显优于对照组;④维拉帕米治疗组治疗12周后复查TC、TG、LDL明显下降,治疗后差异有显著性（P〈0．05）,HDL治疗后升高为（2．73±0．17）,治疗后差异有显著性改善（P〈0．05）,维拉帕米治疗组明显优于对照组。结论维拉帕米与二甲双胍联合用药对高血压合并2型糖尿病（DM）患者具有良好的降压效果及降糖作用。     

神经衰弱的误诊分析及治疗体会

笔者总结了从医20多年来诊治的150例神经衰弱患者,80例首次就医均被误诊,现报道如下。1临床资料1.1一般资料;本组共150例,男49例,女101例。年龄20~59岁,平均40.7岁。(1)症状分布情况:150例有睡眠障碍;141例有衰弱症状;132例有情绪症状;80例有紧张性疼痛症状;98例合并植物神经功     

巴曲酶治疗急性脑梗死临床疗效观察

目的 观察巴曲酶对急性脑梗死的临床疗效.方法 将82例起病在48h内的急性脑梗死患者随机分成观察组和对照组.对照组予脑活素、维脑络通及低分子右旋糖酐治疗,观察组在对照组治疗基础上加用巴曲酶治疗.比较治疗2周后两组的治疗效果.结果 观察组治愈率、总有效率分别是53.3%和100.0%,对照组分别是10.0%和85.0%.两组治愈率和总有效率比较差异有显著性（P＜0.05和P＜0.01）.观察组治疗前后比较,凝血酶原时间无明显改变,而纤维蛋白原降低.结论 巴曲酶治疗急性脑梗死,疗效显著,安全性高,副作用少,值得临床推广应用.     

重组钙调磷酸酶B亚基纯化工艺及质量稳定性控制研究

目的在实验室研究的基础上,已进行了表达rhCNB的中试发酵工艺研究和纯化方面的探讨。表达量可达到700mg/L以上,rhCNB纯度可达到95%以上。方法在此基础上进行了以下两方面工作的研究:①为了达到生物制品的质量标准,进一步改进了rhCNB的纯化工艺。②为了能够对rhCNB进行有效的质量稳定控制,该文对制备的3批注射用rhCNB进行了分子结构确证与理化特性鉴定。结果我们表达的重组hCNB与天然hCNB的结构完全一致。使rhCNB有效期保证在2年以上。     

1996～2000年增城市中小学生法定报告传染病发病趋势分析

<正>1 资料来源及分类依据 资料来源于增城市卫生防疫站统计的1996～2000年法定传染病年报表。根据魏承敏主编的《实用流行病学》(甘肃省科技出版社,1998)的病种分类,分呼吸道、肠道、接触性、动物源性和寄生虫病五大类传染病。中小学生人口资料来源于增城市教育局。2 结果与分析     

维拉帕米二甲双胍联合用药对高血压合并Ⅱ型糖尿病患者降压及降糖作用临床观察

Objective To observe blood pressure lowering effect and the blood glucose lowering effect on the combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (diabetes mellitus, DM). Methods 129 cases of hypertension in patients with type 2 DM were divided into two groups, Verapamil treatment group, 98 cases in the control group 31 cases. (1) Verapamil treatment groups: Verapamil hydrochloride sustained-release capsules 180 mg/d, Metformin 750 ～ 1500 mg/d,Valsartan 80 ～ 160 mg/d, A Division horses Lin 100 mg/d, (2) control group, Valsartan 80 ～ 160 mg/d, Verapamil hydrochloride sustained-release capsules 180 mg/d, Aspirin 100 mg/d. (3) Blood pressure observation: Subjects in patients as early as 7: 00 and 22: 00 evening, measured two times a day and record systolic blood pressure blood pressure decreased significantly compared with those before treatment,4,6 weeks after the blood pressure weeks treatment their difference was significant (P<0.01), but the blood pressure has not dropped to normal ment review TC, TG, LDL decreased significantly after treatment, the difference was significant (P<0.05),HDL increased after treatment of (2.73±0.17), after treatment there was significant difference between improved (P<0.05), Verapamil treatment group was significantly better than the control group. Conclusion The combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (DM) patients has good blood pressure lowering effect and blood glucose lowering effect.     

氨氯地平联合二甲双胍治疗肥胖型轻中度高血压的疗效

目的:观察氨氯地平联合二甲双胍治疗肥胖型轻中度高血压患者的疗效.方法:将90例肥胖型轻中度高血压患者分成3组,观察组30例,给予氨氯地平、二甲双胍治疗;对照组(1)30例,单用氨氯地平治疗;对照组(2)30例,单用二甲双胍治疗.服药前及服药6个月后各组分别测定血压(SBP/DBP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FPG)、空腹血浆胰岛素(FINS)、糖化血红蛋白(HbA1C)及体重指数(BMI)、腰臀比(WHR)等的变化.结果:3组间降压效果比较,观察组>对照组(1)>对照组(2),P<0.05;TG、TC、LDL-C比较,观察组与对照组(2)下降程度差异无显著性(P>0.05),对照组(1)治疗前后无明显变化;FPG、FINS、HbA1C、ISI下降程度比较,观察组>对照组(2)>对照组(1),P<0.05;BMI、WHR下降程度比较,观察组>对照组(2)>对照组(1),P<0.05.结论:氨氯地平能降压、减轻胰岛素抵抗、降低BMI,联合二甲双胍治疗后具有协同作用,且能降低血脂.对肥胖型轻中度高血压患者联合以上两种药物治疗能收到良好的临床效果.     

维拉帕米二甲双胍联合用药对高血压合并Ⅱ型糖尿病患者降压及降糖作用临床观察

Objective To observe blood pressure lowering effect and the blood glucose lowering effect on the combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (diabetes mellitus, DM). Methods 129 cases of hypertension in patients with type 2 DM were divided into two groups, Verapamil treatment group, 98 cases in the control group 31 cases. (1) Verapamil treatment groups: Verapamil hydrochloride sustained-release capsules 180 mg/d, Metformin 750 ～ 1500 mg/d,Valsartan 80 ～ 160 mg/d, A Division horses Lin 100 mg/d, (2) control group, Valsartan 80 ～ 160 mg/d, Verapamil hydrochloride sustained-release capsules 180 mg/d, Aspirin 100 mg/d. (3) Blood pressure observation: Subjects in patients as early as 7: 00 and 22: 00 evening, measured two times a day and record systolic blood pressure blood pressure decreased significantly compared with those before treatment,4,6 weeks after the blood pressure weeks treatment their difference was significant (P<0.01), but the blood pressure has not dropped to normal ment review TC, TG, LDL decreased significantly after treatment, the difference was significant (P<0.05),HDL increased after treatment of (2.73±0.17), after treatment there was significant difference between improved (P<0.05), Verapamil treatment group was significantly better than the control group. Conclusion The combination of Verapamil and Metformin therapy for hypertensive patients with type 2 diabetes mellitus (DM) patients has good blood pressure lowering effect and blood glucose lowering effect.     

C反应蛋白和巨噬细胞移动抑制因子对原发性高血压危险分层的临床意义研究

目的 探讨原发性高血压患者血清C反应蛋白(CRP)、巨噬细胞移动抑制因子(MIF)水平的变化及其对高血压危险分层的临床意义. 方法 选取202例原发性高血压患者为观察组,另取同期健康体检者194例健康成人作为对照组,以酶联免疫吸附法(ELISA)检测CRP及MIF水平,将高血压危险分层分为1～3级,比较1～3级原发性高血压患者CRP及MIF水平. 结果 观察组与对照组受检者血清CRP水平[分别为(21.48±4.30)μg/L与(2.19±2.11)μg/L]、MIF水平[分别为(41.85±4.28)ng/L与(18.71±4.27)ng/L]比较,差异均有统计学意义(P<0.05).高血压1～3级患者血清CRP水平[分别为(18.88±2.75)、(22.52±3.51)、(26.85±3.23)μg/L]、MIF水平[分别为(39.64±3.05)、(42.18±3.53)、(47.28±3.29)ng/L] 比较,差异均有统计学意义(P<0.05).高血压合并动脉粥样硬化者与不合并动脉粥样硬化者CRP水平[分别为(20.69±6.84)、(8.34±8.12)μg/L]、MIF水平[分别为(40.73±7.55)、(26.48±10.89)ng/L] 比较,差异均有统计学意义(P<0.05). 结论 原发性高血压患者危险级别高者CRP及MIF水平亦高,原发性高血压合并动脉粥样硬化患者CRP及MIF水平也升高,提示炎症反应参与了原发性高血压合并动脉粥样硬化的病理生理过程.     

社区精神分裂症病人康复治疗研究

目的探讨社区精神分裂症病人康复治疗的方法。方法对本地区66例患者为研究对象,实施积极的社区康复方法。结果精神残疾严重程度有随治疗持续状况的好转而减轻的趋势。患者的服药落实率和病情显好率明显上升。结论社区康复治疗有利于帮助精神病患者达到心理和社会康复,而且对控制症状也有独到的优点。